ARM I: Patients receive nivolumab intravenously (IV) over 60 minutes once every 2 weeks. Courses repeat every 42 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.